PODCAST · health
Talking About the Data: Chemotherapy and Prostate Cancer
by Sanofi
INDICATION: JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.IMPORTANT SAFETY INFORMATIONWARNING: NEUTROPENIA AND HYPERSENSITIVITY•Neutropenia: Neutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m2.•Severe hypersensitivity: Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy
No episodes available yet.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
INDICATION: JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.IMPORTANT SAFETY INFORMATIONWARNING: NEUTROPENIA AND HYPERSENSITIVITY•Neutropenia: Neutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m2.•Severe hypersensitivity: Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy
HOSTED BY
Sanofi
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Talking About the Data: Chemotherapy and Prostate Cancer have?
Talking About the Data: Chemotherapy and Prostate Cancer currently has 0 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Talking About the Data: Chemotherapy and Prostate Cancer about?
INDICATION: JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.IMPORTANT SAFETY INFORMATIONWARNING: NEUTROPENIA AND...
How often does Talking About the Data: Chemotherapy and Prostate Cancer release new episodes?
Talking About the Data: Chemotherapy and Prostate Cancer is no longer actively publishing new episodes, but the existing catalog remains available.
Where can I listen to Talking About the Data: Chemotherapy and Prostate Cancer?
You can listen to Talking About the Data: Chemotherapy and Prostate Cancer on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Talking About the Data: Chemotherapy and Prostate Cancer?
Talking About the Data: Chemotherapy and Prostate Cancer is created and hosted by Sanofi.
URL copied to clipboard!